A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Active:	Yes
Cancer Type:	Bladder Cancer Kidney Cancer Unknown Primary Ureter Cancer Urethral Cancer	NCT ID:	NCT04879329
Trial Phases:	Phase II	Protocol IDs:	RC48G001 (primary) NCI-2022-03375 2022-500030-28 2022-500030-28-01 C5731002 KEYNOTE-D78 MK-3475-D78 RC48 G001
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Seagen, a wholly owned subsidiary of Pfizer
NCI Full Details:	http://clinicaltrials.gov/show/NCT04879329

Summary

This study is being done to see if a drug called disitamab vedotin, alone or with
pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how
safe the drug is for participants.

Participants will have cancer that has spread in the body near where it started (locally
advanced) and cannot be removed (unresectable) or has spread through the body
(metastatic).

It will also study what side effects happen when participants get the drug. A side effect
is anything a drug does to your body besides treating the disease.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.